The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2022

Filed:

Jan. 08, 2016
Applicants:

Genexine, Inc., Seongnam-si, KR;

Green Cross Corporation, Yongin-si, KR;

Inventors:

Sang-In Yang, Daegu, KR;

Jung-Won Woo, Seoul, KR;

Se Hwan Yang, Seoul, KR;

Young Chul Sung, Seoul, KR;

Doo Hong Park, Seoul, KR;

Min Woo Kim, Seoul, KR;

Assignees:

GENEXINE, INC., Seongnam-si, KR;

GREEN CROSS CORPORATION, Yongin-si, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/46 (2006.01); A61K 38/18 (2006.01); C07K 19/00 (2006.01); A61K 38/16 (2006.01); A61P 7/06 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1816 (2013.01); A61K 9/0019 (2013.01); A61K 38/16 (2013.01); A61K 38/1774 (2013.01); A61K 38/18 (2013.01); A61P 7/06 (2018.01); C07K 19/00 (2013.01); A61K 39/00 (2013.01); C07K 16/00 (2013.01); C07K 16/46 (2013.01);
Abstract

The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.


Find Patent Forward Citations

Loading…